News

Multitude Capital's Financial Statements Showcase Growth

Multitude Capital's Financial Statements Showcase Growth

Multitude Capital Releases Comprehensive Financial Statements

Multitude Capital Oyj has made headlines with the publication of its Financial Statements for the year 2024. As a prominent player in the European FinTech sector, the Company provides valuable insights into its financial health and operational strategies through these documents.

Financial Overview and Audit Results

The financial year 2024 proved pivotal for Multitude. The audit was conducted by the reputable PricewaterhouseCoopers Oy, ensuring that the Financial Statements align with the European Single Electronic Format (ESEF). This audit reflects a thorough analysis of the Company's financial practices and governance, pushing Multitude to the forefront of transparency and accountability.

Key Highlights From the Financial Statements

The Financial Statements comprise detailed reports including the Board of Directors' insights and the Corporate Governance Statement. By adhering to rigorous reporting requirements, Multitude exhibits its commitment to corporate responsibility and investor relations. Investors looking for a comprehensive understanding of the Company's operations will find the attached reports essential.

Growth and Expansion Plans

As a subsidiary of Multitude AG, which is listed and recognized throughout Europe, Multitude Capital has laid the groundwork for future expansion. The Company focuses on lending and banking solutions, attracting both consumers and small to medium-sized enterprises. This dual focus has enabled the Company to build a robust customer base while continuously innovating its product offerings.

Technological Advancements in Service Delivery

In today’s digital age, financial technology is key to success. Multitude has heavily invested in its internal Growth Platform, which supports various business units, including Consumer Banking with Ferratum, SME Banking through CapitalBox, and Wholesale Banking via Multitude Bank. This multi-faceted approach allows for customized financial solutions tailored to diverse client needs.

Employee Growth and Impact

With over 700 employees across 25 countries, Multitude is not just expanding its services but also enhancing local economies. Offering services in 17 countries, the Company achieved an impressive turnover of 264 million euros in 2024 alone. These figures underscore Multitude's significant impact in the FinTech landscape and its dedication to creating sustainable business practices.

Contact Information

For inquiries or further information regarding the Financial Statements or other corporate matters, please reach out to:

Bernd Egger
Chief Financial Officer
Phone: +49 173 7931235
Email: bernd.egger@multitude.com

Frequently Asked Questions

1. What are the main highlights of the Financial Statements for 2024?

The Financial Statements highlight significant growth, a thorough audit by PricewaterhouseCoopers Oy, and a dedicated commitment to transparency.

2. Who conducted the audit for Multitude Capital?

PricewaterhouseCoopers Oy conducted a comprehensive audit to ensure compliance with ESEF standards.

3. What services does Multitude Capital offer?

Multitude Capital provides digital lending and online banking services, focusing on consumers, SMEs, and other FinTechs.

4. How many employees does Multitude Capital have?

Multitude Capital employs over 700 individuals in 25 countries, showcasing its international reach.

5. Where can I find the detailed reports?

The detailed reports are available in both pdf and XHTML formats, attached to the official release.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Embla Medical hf Reports Strong Q2 2025 Financial Performance

Updated Category News Views 203

Embla Medical hf's Interim Report for Q2 2025 Announcement No. 33/2025 Interim Report Q2 2025 Embla Medical hf has recently published its interim report for the second quarter of 2025, revealing encouraging financial results. The organization remains committed to enhancing mobility solutions through innovative offerings in prosthetics and orthotics. Strong Sales Growth...

Continue Reading
Fly-E Group Faces Important Class Action Deadline for Investors

Updated Category News Views 185

Fly-E Group Update: Important Class Action Deadline Attention investors of Fly-E Group, Inc. If you purchased securities between July 15 and August 14, 2025, this is vital news for you. As we approach a crucial lead plaintiff deadline on November 10, 2025, the time to act is now. Understanding the Class Action The upcoming class action lawsuit revolves around Fly-E's...

Continue Reading
Royal Unibrew Posts Impressive Earnings Growth in Q3 2024

Updated Category News Views 173

Royal Unibrew's Remarkable Performance in Q3 2024 Royal Unibrew has demonstrated exceptional growth during the third quarter of 2024. The key highlights from this trading statement reveal a robust progression in organic volume and net revenue, paving the way for a bright future for the company. Strong Growth Metrics Organic Volume and Revenue Increases During Q3 2024,...

Continue Reading
Examining Medtronic PLC's Short Selling Trends and Insights

Updated Category News Views 184

Understanding Medtronic PLC's Short Interest Medtronic PLC (NYSE: MDT) has recently experienced a significant rise in its short interest as a percentage of float, currently at 17.56%. This increase signals a growing concern among investors, as the total number of shares sold short has reached 19.72 million, accounting for 1.54% of all available shares for trading. With...

Continue Reading
Palatin Technologies Announces Breakthrough in Obesity Management

Updated Category News Views 138

Positive Developments in Appetite Suppression Research Palatin Technologies, Inc. (NYSE American: PTN), a leading biopharmaceutical firm known for pioneering medications based on the melanocortin receptor system, has recently reported encouraging results concerning appetite suppression from its Phase 2 obesity study involving bremelanotide and tirzepatide. This...

Continue Reading